Log In Get Started
Press Releases July 20, 2026 08:30 AM

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

ORIC Pharmaceuticals to present multiple clinical trial updates at ESMO Congress 2026 highlighting promising oncology drug candidates.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
ORIC

ORIC Pharmaceuticals announced three poster presentations at the ESMO Congress 2026 showcasing data on its clinical stage oncology drugs enozertinib and rinzimetostat. These presentations include early-phase trial results of enozertinib for first-line treatment of atypical EGFR mutated NSCLC and ongoing Phase 3 trial design and preclinical mechanistic data for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC).

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
ORIC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Enozertinib data from a Phase 1b trial in treatment-naive metastatic NSCLC patients with atypical EGFR mutations will be presented.
  • Rinzimetostat Phase 3 study design (Himalayas-1) in mCRPC patients previously treated with abiraterone will be shared as a trial-in-progress poster.
  • Preclinical data support rinzimetostat’s potential to enhance androgen receptor signaling and restrict lineage plasticity in mCRPC, demonstrating mechanistic proof-of-concept.

Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC

Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone

Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Poster presentation details:

Title:Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical MutationsPresentation Number:2627PSession Date & Time:Monday, October 26, 2026; 12:00 – 12:45 p.m. CETSession Title: Metastatic NSCLC  Title:Rinzimetostat, an Allosteric PRC2 Inhibitor Combined With Darolutamide: A Global Phase 3 Study in mCRPC Patients Previously Treated With Abiraterone Acetate (Himalayas-1)Presentation Number:2303TiPSession Date & Time:Friday, October 23, 2026; 3:15 – 4:00 p.m. CESTSession Title:Metastatic Prostate Cancer  Title:Rinzimetostat, a Next-Generation PRC2 Inhibitor, Enhances Luminal Fate and AR Signaling While Restricting Lineage Plasticity in Preclinical Models and Demonstrates Mechanistic
Proof-of-Concept in Samples From Patients with mCRPCPresentation Number:1128ePSession Title: Developmental Therapeutics  

Full abstracts will be available for public viewing via the ESMO Congress website on October 19, 2026.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
[email protected]
[email protected]


Risks

  • Clinical trial risks exist as the drugs are in early and mid-stage development, and positive data is not guaranteed to translate into approval or commercial success.
  • Potential regulatory uncertainties could delay or impact drug approvals based on forthcoming trial results.
  • Competition in oncology drug development, particularly for NSCLC and prostate cancer treatments, could impact ORIC’s market penetration if other therapies show superior efficacy or safety.

More from Press Releases

Zoom appoints Carlos Quaderi as Head of APAC to drive next phase of AI-powered growth Jul 20, 2026 Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress Jul 20, 2026 Columbia Financial, Inc. Announces Completion of Second Step Conversion and $1.7 Billion Stock Offering and Acquisition of Northfield Bancorp, Inc. Jul 20, 2026 Quantum BioPharma Announces Intention to Settle Debt Jul 20, 2026 AMR Resources Acquisition Corp Announces Closing of $260,000,000 Initial Public Offering, Including Partial Exercise of Underwriters’ Over-Allotment Option Jul 20, 2026